Other News

Neovasc Announces Second Quarter Financial Results

VANCOUVER and MINNEAPOLIS, MN, Aug. 06, 2020 (GLOBE NEWSWIRE) —  via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended […]

Cytokinetics Reports Second Quarter 2020 Financial Results

Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capital to Support Commercial Development and Pipeline Expansion; Company Expects to End 2020 With More Than $500 Million Cash SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]

CARMAT Announces the Publication of the Bridge-to-transplant Experience in the Journal of Heart and Lung Transplantation

The 5 successful transplants performed during the PIVOTAL study point to the efficacy of the CARMAT heart for patients waiting for a graft CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage […]

InnovHeart Appoints J. Brent Ratz as Chief Executive Officer and Member of the Board

NEWTON, Mass.–(BUSINESS WIRE)–InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral regurgitation, announced today the appointment of veteran medical device executive J. Brent Ratz to the role of Chief Executive Officer of the company and executive member of the Board of Directors. Brent Ratz […]

Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer

BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that Joseph Talamo, Chief Financial Officer (“CFO”), has tendered his resignation in […]